May 4th, 2022 · Common Contracts · 1000 similar Creative Medical Technology Holdings, Inc. – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
October 28th, 2021 · Common Contracts · 1000 similar SAB Biotherapeutics, Inc. – FORM OF INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of ___________, 2021, by and between Big Cypress Acquisition Corp., a Delaware corporation (the “Company”), and (“Indemnitee”).
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of ___________, 2021, by and between Big Cypress Acquisition Corp., a Delaware corporation (the “Company”), and (“Indemnitee”).
May 4th, 2022 · Common Contracts · 1000 similar Creative Medical Technology Holdings, Inc. – REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 29, 2022, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
November 10th, 2020 · Common Contracts · 1000 similar BioNTech SE – BioNTech SE as the Company and Wilmington Trust, National Association as Trustee Indenture Dated as of [ ] Subordinated Debt Securities INDENTURE, dated as of [ ], between BioNTech SE, a European stock corporation (Societas Europaea) incorporated in Germany and governed by the laws of the European Union and the Federal Republic of Germany and registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Mainz, Federal Republic of Germany, under number HRB 48720 (the “Company”), having its principal office at An der Goldgrube 12, D-55131 Mainz, Germany and Wilmington Trust, National Association, as Trustee (the “Trustee”).
INDENTURE, dated as of [ ], between BioNTech SE, a European stock corporation (Societas Europaea) incorporated in Germany and governed by the laws of the European Union and the Federal Republic of Germany and registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Mainz, Federal Republic of Germany, under number HRB 48720 (the “Company”), having its principal office at An der Goldgrube 12, D-55131 Mainz, Germany and Wilmington Trust, National Association, as Trustee (the “Trustee”).
November 17th, 2020 · Common Contracts · 1000 similar Cytrx Corp – CYTRX CORPORATION and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent AMENDED AND RESTATED RIGHTS AGREEMENT dated as of November 16, 2020 This AMENDED AND RESTATED RIGHTS AGREEMENT, dated as of November 16, 2020 (this “Agreement”), is made and entered into by and between CytRx Corporation, a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agent”).
This AMENDED AND RESTATED RIGHTS AGREEMENT, dated as of November 16, 2020 (this “Agreement”), is made and entered into by and between CytRx Corporation, a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agent”).
February 4th, 2022 · Common Contracts · 1000 similar BioAtla, Inc. – BIOATLA, INC. AND as Trustee, INDENTURE Dated as of Debt Securities INDENTURE (the “Indenture”), dated as of ______________, between BioAtla, Inc., a corporation existing under the laws of the State of Delaware (the “Company”), and ______________, as trustee (the “Trustee”).
INDENTURE (the “Indenture”), dated as of ______________, between BioAtla, Inc., a corporation existing under the laws of the State of Delaware (the “Company”), and ______________, as trustee (the “Trustee”).
May 24th, 2022 · Common Contracts · 1000 similar Halozyme Therapeutics, Inc. – CREDIT AGREEMENT Dated as of May 24, 2022 among HALOZYME THERAPEUTICS, INC., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, a Swing Line Lender and an L/C Issuer, and The Other Lenders and L/C Issuers Party Hereto BofA SECURITIES,... This CREDIT AGREEMENT (“Agreement”) is entered into as of May 24, 2022, among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), HALOZYME, INC., a California corporation, each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), each L/C Issuer (as hereinafter defined) from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent and Swing Line Lender.
This CREDIT AGREEMENT (“Agreement”) is entered into as of May 24, 2022, among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), HALOZYME, INC., a California corporation, each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), each L/C Issuer (as hereinafter defined) from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent and Swing Line Lender.
May 4th, 2022 · Common Contracts · 990 similar Cannabis Global, Inc. – SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 28, 2022, by and between CANNABIS GLOBAL, INC., a Nevada corporation, with headquarters located at 520 S. Grand Avenue, Suite 320, Los Angeles, CA 90071 (the “Company”), and SUGARMADE, INC., a Delaware corporation, for the benefit of its wholly owned subsidiary, LEMON GLOW COMPANY, INC., a California corporation
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 28, 2022, by and between CANNABIS GLOBAL, INC., a Nevada corporation, with headquarters located at 520 S. Grand Avenue, Suite 320, Los Angeles, CA 90071 (the “Company”), and SUGARMADE, INC., a Delaware corporation, for the benefit of its wholly owned subsidiary, LEMON GLOW COMPANY, INC., a California corporation
March 15th, 2022 · Common Contracts · 925 similar Molecular Partners Ag – DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of June 18, 2021 DEPOSIT AGREEMENT, dated as of June 18, 2021, by and among (i) MOLECULAR PARTNERS AG, a corporation incorporated under the laws of Switzerland, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
DEPOSIT AGREEMENT, dated as of June 18, 2021, by and among (i) MOLECULAR PARTNERS AG, a corporation incorporated under the laws of Switzerland, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
May 4th, 2022 · Common Contracts · 914 similar Tarsus Pharmaceuticals, Inc. – a Delaware corporation) 5,600,000 Shares of Common Stock UNDERWRITING AGREEMENT Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Jefferies LLC (“Jefferies”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and Jefferies are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 840,000 additional shares of Common Stock. The aforesaid 5,600,000 shares of Common Stock (the “Initial Securit
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Jefferies LLC (“Jefferies”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and Jefferies are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 840,000 additional shares of Common Stock. The aforesaid 5,600,000 shares of Common Stock (the “Initial Securit
May 24th, 2022 · Common Contracts · 791 similar TC BioPharm (Holdings) PLC – UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON, division of Benchmark Investments, LLC, as Representative of the Several Underwriters UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON division of... The undersigned, TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended (the “Companies Act”) with company number SC713098 (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with EF Hutton, division of Benchmark Investments, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”), and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
The undersigned, TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended (the “Companies Act”) with company number SC713098 (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with EF Hutton, division of Benchmark Investments, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”), and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
August 25th, 2011 · Common Contracts · 786 similar Nabi Biopharmaceuticals – Nabi Biopharmaceuticals and American Stock Transfer & Trust Company, LLC as Rights Agent Rights Agreement Dated as of August 25, 2011 Until the earlier to occur of (i) the tenth business day following a public announcement that a person or group of affiliated or associated persons has acquired beneficial ownership of 4.99% or more of the Common Stock (an “Acquiring Person”) or (ii) ten Business Days (or such later date as may be determined by action of the Board of Directors prior to such time as any person or group of affiliated persons becomes an Acquiring Person) following the commencement or announcement of an intention to make a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 4.99% or more of the Common Stock (the earlier of (i) and (ii) being called the “Distribution Date”), the Rights will be evidenced, with respect to any of the Common Stock certificates outstanding as of the Record Date, by such Common Stock certificate (or, with respect to any shares of Common Stock held in book entry form, by the notation in book entry) together with
Until the earlier to occur of (i) the tenth business day following a public announcement that a person or group of affiliated or associated persons has acquired beneficial ownership of 4.99% or more of the Common Stock (an “Acquiring Person”) or (ii) ten Business Days (or such later date as may be determined by action of the Board of Directors prior to such time as any person or group of affiliated persons becomes an Acquiring Person) following the commencement or announcement of an intention to make a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 4.99% or more of the Common Stock (the earlier of (i) and (ii) being called the “Distribution Date”), the Rights will be evidenced, with respect to any of the Common Stock certificates outstanding as of the Record Date, by such Common Stock certificate (or, with respect to any shares of Common Stock held in book entry form, by the notation in book entry) together with
October 12th, 2021 · Common Contracts · 686 similar MiNK Therapeutics, Inc. – INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [_________], 2021, between MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [_________], 2021, between MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).
April 6th, 2015 · Common Contracts · 681 similar BiondVax Pharmaceuticals Ltd. – BIONDVAX PHARMACEUTICALS LTD. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement Dated as of _______________, 2015 DEPOSIT AGREEMENT DEPOSIT AGREEMENT dated as of ________________, 2015, among BiondVax Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
DEPOSIT AGREEMENT dated as of ________________, 2015, among BiondVax Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
December 28th, 2021 · Common Contracts · 670 similar Arcellx, Inc. – ARCELLX, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Arcellx, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Arcellx, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
January 31st, 2022 · Common Contracts · 627 similar Arcellx, Inc. – Number of Shares] Arcellx, Inc. UNDERWRITING AGREEMENT
April 18th, 2022 · Common Contracts · 599 similar HilleVax, Inc. – HILLEVAX, INC. [•] Shares of Common Stock Underwriting Agreement HilleVax, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
HilleVax, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
January 13th, 2021 · Common Contracts · 549 similar Cannabis Global, Inc. – SECURITIES PURCHASE AGREEMENT This SECUITIES PURCHASE AGREEMENT (the "Agreement"), dated as of January 12, 2021, by and between Cannabis Global, Inc., a Nevada corporation, with headquarters located at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071 (the "Company'), and GW Holdings Group, LLC, a New York limited liability company with its executive offices located at 137 Montague Street, Suite 291, Brooklyn, NY 11201 (the "Buyer").
This SECUITIES PURCHASE AGREEMENT (the "Agreement"), dated as of January 12, 2021, by and between Cannabis Global, Inc., a Nevada corporation, with headquarters located at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071 (the "Company'), and GW Holdings Group, LLC, a New York limited liability company with its executive offices located at 137 Montague Street, Suite 291, Brooklyn, NY 11201 (the "Buyer").
May 18th, 2017 · Common Contracts · 532 similar Premier Biomedical Inc – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2017, between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2017, between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
August 19th, 2020 · Common Contracts · 467 similar Momenta Pharmaceuticals Inc – AGREEMENT AND PLAN OF MERGER by and among JOHNSON & JOHNSON, VIGOR SUB, INC. and MOMENTA PHARMACEUTICALS, INC. Dated as of August 19, 2020 THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 19, 2020 by and among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), VIGOR SUB, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 19, 2020 by and among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), VIGOR SUB, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
June 21st, 2001 · Common Contracts · 449 similar Sangstat Medical Corp – REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of June 20, 2001, by and among SangStat Medical Corporation, a corporation organized under the laws of the State of Delaware (the "Company"), and the undersigned (together with their affiliates, the "Initial Investors").
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of June 20, 2001, by and among SangStat Medical Corporation, a corporation organized under the laws of the State of Delaware (the "Company"), and the undersigned (together with their affiliates, the "Initial Investors").
December 23rd, 2021 · Common Contracts · 431 similar TC BioPharm (Holdings) LTD – TC BIOPHARM (HOLDINGS) PLC AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement DEPOSIT AGREEMENT dated as of __________, 2021 among TC BIOPHARM (HOLDINGS) PLC, a company incorporated under the laws of Scotland (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
DEPOSIT AGREEMENT dated as of __________, 2021 among TC BIOPHARM (HOLDINGS) PLC, a company incorporated under the laws of Scotland (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
September 6th, 2016 · Common Contracts · 426 similar AveXis, Inc. – Underwriting Agreement AveXis, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”) an aggregate of [·] shares (the “Company Firm Shares”) and, at the election of the Underwriters, up to [·] additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company. PBM Capital Investments, LLC (the “Selling Stockholder”) proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters an aggregate of [·] shares (the “Selling Stockholder Firm Shares” and together with the Company Firm Shares, the “Firm Shares”) of Stock of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
AveXis, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”) an aggregate of [·] shares (the “Company Firm Shares”) and, at the election of the Underwriters, up to [·] additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company. PBM Capital Investments, LLC (the “Selling Stockholder”) proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters an aggregate of [·] shares (the “Selling Stockholder Firm Shares” and together with the Company Firm Shares, the “Firm Shares”) of Stock of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
August 2nd, 2021 · Common Contracts · 419 similar Adagio Therapeutics, Inc. – •] Shares ADAGIO THERAPEUTICS, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT
November 10th, 2021 · Common Contracts · 417 similar C4 Therapeutics, Inc. – C4 THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities
September 1st, 2017 · Common Contracts · 405 similar Acorda Therapeutics Inc – ACORDA THERAPEUTICS, INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent Rights Agreement Dated as of August 31, 2017 Rights Agreement, dated as of August 31, 2017 (as amended, supplemented or otherwise modified from time to time, the “Agreement”), between Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), and COMPUTERSHARE TRUST COMPANY, N.A., a federally chartered trust company, as rights agent (the “Rights Agent”).
Rights Agreement, dated as of August 31, 2017 (as amended, supplemented or otherwise modified from time to time, the “Agreement”), between Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), and COMPUTERSHARE TRUST COMPANY, N.A., a federally chartered trust company, as rights agent (the “Rights Agent”).
January 13th, 2021 · Common Contracts · 400 similar Cannabis Global, Inc. – SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of October 30, 2020, by and between CANNABIS GLOBAL, INC. f/k/a MCTC HOLDINGS, INC., a Nevada corporation, with its address at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071 (the "Company"), and REDSTART HOLDINGS CORP., a New York corporation, with its address at 1188 Willis Avenue, Albertson, New York 11507 (the "Buyer").
This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of October 30, 2020, by and between CANNABIS GLOBAL, INC. f/k/a MCTC HOLDINGS, INC., a Nevada corporation, with its address at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071 (the "Company"), and REDSTART HOLDINGS CORP., a New York corporation, with its address at 1188 Willis Avenue, Albertson, New York 11507 (the "Buyer").
August 3rd, 2011 · Common Contracts · 400 similar NPS Pharmaceuticals Inc – NPS PHARMACEUTICALS, INC. as Issuer to [ ], as Trustee FORM OF SENIOR INDENTURE Dated as of , 201 INDENTURE, dated as of , 201 , among NPS PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), having its principal office at 550 Hills Drive, 3rd Fl., Bedminster, New Jersey 07921, and [ ], a national banking association, as Trustee (herein called the “Trustee”).
INDENTURE, dated as of , 201 , among NPS PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), having its principal office at 550 Hills Drive, 3rd Fl., Bedminster, New Jersey 07921, and [ ], a national banking association, as Trustee (herein called the “Trustee”).
March 9th, 2020 · Common Contracts · 399 similar NanoString Technologies Inc – NANOSTRING TECHNOLOGIES, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 9, 2020 2.625% Convertible Senior Notes due 2025 INDENTURE, dated as of March 9, 2020, between NANOSTRING TECHNOLOGIES, INC., a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
INDENTURE, dated as of March 9, 2020, between NANOSTRING TECHNOLOGIES, INC., a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
August 8th, 2006 · Common Contracts · 385 similar Ariad Pharmaceuticals Inc – FORM OF INDEMNITY AGREEMENT This Indemnity Agreement (“Agreement”) is made as of ________, ____ by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
This Indemnity Agreement (“Agreement”) is made as of ________, ____ by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
October 3rd, 2008 · Common Contracts · 380 similar Advanced Life Sciences Holdings, Inc. – REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of the 29th day of September 2008 (this “Agreement”) between YA GLOBAL INVESTMENTS, L.P., a Cayman Islands exempt limited partnership (the “Investor”), and ADVANCED LIFE SCIENCES HOLDINGS, INC., a corporation organized and existing under the laws of the State of Delaware (the “Company”)
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of the 29th day of September 2008 (this “Agreement”) between YA GLOBAL INVESTMENTS, L.P., a Cayman Islands exempt limited partnership (the “Investor”), and ADVANCED LIFE SCIENCES HOLDINGS, INC., a corporation organized and existing under the laws of the State of Delaware (the “Company”)
March 16th, 2022 · Common Contracts · 374 similar Axcella Health Inc. – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 16, 2022, between Axcella Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of March 16, 2022, between Axcella Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
August 26th, 2021 · Common Contracts · 374 similar Cannabis Global, Inc. – REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 23, 2021, by and between CANNABIS, GLOBAL INC., a Nevada corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND LP, a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the common stock purchase agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented, or otherwise modified from time to time, the “Purchase Agreement”).
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 23, 2021, by and between CANNABIS, GLOBAL INC., a Nevada corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND LP, a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the common stock purchase agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented, or otherwise modified from time to time, the “Purchase Agreement”).
August 23rd, 2021 · Common Contracts · 370 similar PharmaCyte Biotech, Inc. – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 19, 2021, between PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of August 19, 2021, between PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
February 22nd, 2011 · Common Contracts · 362 similar Medgenics, Inc. – WARRANT AGREEMENT This Warrant Agreement made as of [___________], 2011, is between Medgenics, Inc., a Delaware corporation, with offices at 8000 Towers Crescent Drive, Suite 1300, Vienna, Virginia 22182, (the “Company”), and Corporate Stock Transfer, Inc. with offices at 3200 Cherry Creek Drive South, Suite 4300, Denver, Colorado 80209 (the “Warrant Agent”).
This Warrant Agreement made as of [___________], 2011, is between Medgenics, Inc., a Delaware corporation, with offices at 8000 Towers Crescent Drive, Suite 1300, Vienna, Virginia 22182, (the “Company”), and Corporate Stock Transfer, Inc. with offices at 3200 Cherry Creek Drive South, Suite 4300, Denver, Colorado 80209 (the “Warrant Agent”).